Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study

被引：86

作者：

Hu, Jiao ^{[1
,2
]}

Chen, Jinbo ^{[1
,2
]}

Ou, Zhenyu ^{[1
,2
,4
]}

Chen, Haige ^{[3
]}

Liu, Zheng

Chen, Minfeng ^{[1
,2
]}

Zhang, Ruiyun ^{[3
]}

Yu, Anze ^{[5
]}

Cao, Rui ^{[6
]}

Zhang, Enchong ^{[7
]}

Guo, Xi ^{[8
]}

Peng, Bo ^{[9
]}

Deng, Dingshan ^{[1
,2
]}

Cheng, Chunliang ^{[1
,2
]}

Liu, Jinhui ^{[1
,2
]}

Li, Huihuang ^{[1
,2
]}

Zou, Yihua ^{[10
]}

Deng, Ruoping ^{[11
]}

Qin, Gang ^{[11
]}

Li, Wenze

Wang, Lue ^{[12
,13
]}

Chen, Tao ^{[14
]}

Pei, Xiaming ^{[15
]}

Gong, Guanghui ^{[16
]}

Tang, Jiansheng ^{[17
]}

Othmane, Belaydi ^{[1
,2
]}

Cai, Zhiyong ^{[1
,2
]}

Zhang, Chunyu ^{[1
,2
]}

Liu, Zhi ^{[1
,2
]}

Zu, Xiongbing ^{[1
,2
]}

机构：

[1] Cent South Univ, Xiangya Hosp, Dept Urol, Changsha, Peoples R China

[2] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China

[3] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Urol, Shanghai, Peoples R China

[4] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Urol, Wuhan, Peoples R China

[5] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou, Peoples R China

[6] Capital Med Univ, Beijing Friendship Hosp, Dept Urol, Beijing, Peoples R China

[7] China Med Univ, Shengjing Hosp, Dept Urol, Shenyang, Peoples R China

[8] Hunan Normal Univ, Hunan Prov Peoples Hosp, Affiliated Hosp 1, Dept Urol, Changsha, Peoples R China

[9] Zhangjiajie Peoples Hosp, Dept Urol, Zhangjiajie, Peoples R China

[10] First Peoples Hosp Chenzhou, Dept Urol, Chenzhou, Peoples R China

[11] Cent Hosp Yongzhou, Dept Urol, Yongzhou, Peoples R China

[12] First Peoples Hosp Xiangtan City, Dept Urol, Xiangtan, Peoples R China

[13] Huarong Peoples Hosp, Dept Urol, Yueyang, Peoples R China

[14] Xiangyang Cent Hosp, Dept Urol, Xiangyang, Peoples R China

[15] Hunan Canc Hosp, Dept Urol, Changsha, Peoples R China

[16] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha, Peoples R China

[17] Xiangnan Univ, Affiliated Hosp, Dept Urol, Chenzhou, Peoples R China

来源：

CELL REPORTS MEDICINE | 2022年 / 3卷 / 11期

基金：

中国国家自然科学基金; 湖南省自然科学基金;

关键词：

PHASE-III TRIAL; UROTHELIAL CARCINOMA; TUMOR MICROENVIRONMENT; OPEN-LABEL; END-POINT; PEMBROLIZUMAB; CISPLATIN; OUTCOMES; TISLELIZUMAB; ATEZOLIZUMAB;

D O I：

10.1016/j.xcrm.2022.100785

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

To parallelly compare the efficacy of neoadjuvant immunotherapy (tislelizumab), neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination therapy (tislelizumab + GC) in patients with mus-cle-invasive bladder cancer (MIBC) and explore the efficacy predictors, we perform a multi-center, real-world cohort study that enrolls 253 patients treated with neoadjuvant treatments (combination therapy: 98, chemo-therapy: 107, and immunotherapy: 48) from 15 tertiary hospitals. We demonstrate that neoadjuvant combi-nation therapy achieves the highest complete response rate and pathological downstaging rate compared with neoadjuvant immunotherapy or chemotherapy. We develop and validate an efficacy prediction model consisting of pretreatment clinical characteristics, which can pinpoint candidates to receive neoadjuvant combination therapy. We also preliminarily reveal that patients who achieve pathological complete response after neoadjuvant treatments plus maximal transurethral resection of the bladder tumor may be safe to receive bladder preservation therapy. Overall, this study highlights the benefit of neoadjuvant combination therapy based on tislelizumab for MIBC.

引用

页数：17

共 50 条

[41] Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer [J].

Jiang, Di ;

Jiang, Haiyan ;

Chung, Peter W. M. ;

Zlotta, Alexandre R. ;

Fleshner, Neil Eric ;

Bristow, Robert G. ;

Berlin, Alejandro ;

Kulkarni, Girish S. ;

Alimohamed, Nimira S. ;

Lo, Gregory ;

Sridhar, Srikala S. .

CLINICAL GENITOURINARY CANCER, 2019, 17 (01) :38-45

[42] The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study [J].

Kaiser, Jeenan ;

Li, Haocheng ;

North, Scott A. ;

Leibowitz-Amit, Raya ;

Seah, Jo-An ;

Morshed, Nisha ;

Chau, Caroline ;

Lee-Ying, Richard ;

Heng, Daniel Y. C. ;

Sridhar, Srikala ;

Crabb, Simon J. ;

Alimohamed, Nimira S. .

BLADDER CANCER, 2018, 4 (02) :185-194

[43] Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer [J].

Narayan, Vivek ;

Mamtani, Ronac ;

Keefe, Stephen ;

Guzzo, Thomas ;

Malkowicz, S. Bruce ;

Vaughn, David J. .

CANCER RESEARCH AND TREATMENT, 2016, 48 (03) :1084-1091

[44] Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI [J].

Brembilla, Giorgio ;

Basile, Giuseppe ;

Cosenza, Michele ;

Giganti, Francesco ;

Del Prete, Andrea ;

Russo, Tommaso ;

Pennella, Renato ;

Lavalle, Salvatore ;

Raggi, Daniele ;

Mercinelli, Chiara ;

Tateo, Valentina ;

Cigliola, Antonio ;

Patane, Damiano ;

Crupi, Emanuele ;

Giannatempo, Patrizia ;

Messina, Antonella ;

Calareso, Giuseppina ;

Martini, Alberto ;

Bandini, Marco ;

Moschini, Marco ;

Cardone, Gianpiero ;

Briganti, Alberto ;

Montorsi, Francesco ;

Necchi, Andrea ;

De Cobelli, Francesco .

RADIOLOGY, 2024, 313 (03)

[45] Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Are We Asking the Right Questions? [J].

Aragon-Ching, Jeanny B. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (36) :4169-4170

[46] Predictive Biomarkers for Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer: A survey [J].

Abdeltawab, Hisham ;

Khalifa, Fahmi ;

Ghazal, Mohammed ;

Haddad, Ahmed ;

Mohamed, Tamer ;

Giridharan, Guruprasad ;

El-Baz, Ayman .

2018 IEEE INTERNATIONAL SYMPOSIUM ON SIGNAL PROCESSING AND INFORMATION TECHNOLOGY (ISSPIT), 2018, :423-428

[47] Predictive Biomarkers for Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer: A survey [J].

Abdeltawab, Hisham ;

Khalifa, Fahmi ;

Ghazal, Mohammed ;

Haddad, Ahmed ;

Mohamed, Tamer ;

Giridharan, Guruprasad ;

El-Baz, Ayman .

2018 IEEE INTERNATIONAL SYMPOSIUM ON SIGNAL PROCESSING AND INFORMATION TECHNOLOGY (ISSPIT), 2018, :270-275

[48] Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm? [J].

Pederzoli, Filippo ;

Bandini, Marco ;

Marandino, Laura ;

Raggi, Daniele ;

Giannatempo, Patrizia ;

Salonia, Andrea ;

Gallina, Andrea ;

Briganti, Alberto ;

Montorsi, Francesco ;

Necchi, Andrea .

EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (06) :1006-1010

[49] Increasing Utilization of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer in the United States [J].

Keegan, Kirk A. ;

Zaid, Harras B. ;

Patel, Sanjay G. ;

Chang, Sam S. .

CURRENT UROLOGY REPORTS, 2014, 15 (04)

[50] Usefulness of neoadjuvant chemotherapy in non-metastatic muscle-invasive bladder cancer [J].

Esper Rueda, J. A. ;

Carrion Lopez, P. ;

Donate Moreno, M. J. ;

Herais Raya, L. ;

Sanchez Migallon, I. Diaz de Mera ;

Legido Gomez, O. ;

Rico Marco, S. ;

Martinez Ruiz, J. ;

Nogueron Martinez, E. ;

Salinas Sanchez, A. S. .

ACTAS UROLOGICAS ESPANOLAS, 2021, 45 (04) :300-308

← 1 2 3 4 5 →